Life-threatening interaction of mibefradil and β-blockers with dihydropyridine calcium channel blockers

JAMA

Volumn 280, Issue 2, 1998, Pages 157-158

  Mullins, Michael E ^a,d   Horowitz, B Zane ^a   Linden, Dennis H J ^b   Smith, Gregory W ^c   Norton, Robert L ^a   Stump, Jack ^b  

^a Oregon Poison Center   (United States)

^b Rogue Valley Medical Center   (United States)

^c Louisiana Poison Control Center   (United States)

^d Mail Code CB 550   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FELODIPINE; FOLIC ACID; GLIBENCLAMIDE; GLIMEPIRIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; MIBEFRADIL; NADOLOL; NIFEDIPINE; NISOLDIPINE; OMEPRAZOLE; OXAPROZIN; PROPRANOLOL; QUINAPRIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOGENIC SHOCK; CASE REPORT; COMORBIDITY; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0032496879     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.2.157     Document Type: Article

References (14)

1. Mibefradil: a new calcium channel blocker. Med Lett. 1997;39:103-105.
2. Neergaard L. Heart drug pulled from market. Associated Press. June 8, 1998.
3. Voluntary market withdrawal, Posicor [Dear Doctor letter]. Nutley, NJ: Roche Laboratories Inc; June 8, 1998.
4. Kobrin I, Charlon V, Lindberg E, Pordy R. Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist. Am J Cardiol. 1997;80: 40C-46C.
5. Bursztyn M, Kadr H, Tilvis R, et al. Mibefradil, a novel calcium channel antagonist, in elderly patients with hypertension: favorable hemodynamics and pharmacokinetics. Am Heart J. 1997;134:238-247.
6. Alpert JS, Kobrin I, DeQuattro V, et al. Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta-blocker for chronic stable angina pectoris. Am J Cardiol. 1997; 79:1025-1030.
7. Dear Doctor letter. Nutley, NJ: Roche Laboratories Inc; December 18, 1997.
8. Posicor [package insert]. Nutley, NJ: Hoffman-La Roche; December 1997.
9. Important information on drug interaction and therapy substitution for Posicor [Dear Doctor letter]. Nutley, NJ: Roche Laboratories Inc; June 12, 1998.
10. Doyon S, Roberts JR. The use of glucagon in a case of calcium channel blocker overdose. Ann Emerg Med. 1993;22:1229-1233.
11. Walter FG, Frye G, Mullen JT, Ekins BR, Khasigian PA. Amelioration of nifedipine poisoning associated with glucagon therapy. Ann Emerg Med. 1993;22:1234-1237.
12. Bey TA, Walter FG. Glucagon and phenol toxicily. Ann Emerg Med. 1997;30:353-354.
13. Horowitz BZ, Rhee KJ. Massive verapamil ingestion: a report of two cases and a review of the literature. Am J Emerg Med. 1989;7:624-631.
14. Wolf LR, Spadafora MP, Otten EJ. Use of amrinone and glucagon in a case of calcium channel blocker overdose. Ann Emerg Med. 1993;22:1225.